FIRST-IN-HUMAN PHASE I/IB DOSE-FINDING STUDY OF ADAGRASIB (MRTX849) IN PATIENTS

Tuesday, July 26, 2022

Read the Story Here

Related Posts

Discover more posts like this.

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

Dec 2, 2024

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Oct 25, 2024

Dr. Minal Barve

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Oct 14, 2024

Dr. Minal Barve
See All Posts